Table 2.
Comparison of change in clinical parameters before and after administration of placebo or empagliflozin
| Placebo | EMPA | P‐value | |
|---|---|---|---|
| ΔBW (kg) | 0.57 ± 1.28 | −3.10 ± 2.02 | 0.001176* |
| ΔBMI | 0.32 ± 0.61 | −1.11 ± 0.94 | 0.004555* |
| ΔFBG (mg/dL) | −2.6 ± 18.8 | −10.9 ± 23.0 | 0.0448* |
| ΔHbA1c (%) | −0.07 ± 0.37 | −0.49 ± 1.1 | 0.0295* |
| ΔIRI (μU/mL) | 0.17 ± 0.62 | −1.06 ± 0.84 | < 0.001* |
| ΔHOMA‐R | 0.1 ± 0.437 | −0.54 ± 1.11 | 0.0105* |
| ΔLDL‐C (mg/dL) | 4.13 ± 16.0 | 2.44 ± 15.8 | 0.695 |
| ΔHDL‐C (mg/dL) | 0.40 ± 6.3 | 1.4 ± 5.4 | 0.504 |
| ΔTG (mg/dL) | −2.0 ± 30.6 | −9.2 ± 47.2 | 0.486 |
| ΔRLP‐C mg/dL) | 0.51 ± 5.5 | −0.51 ± 5.5 | 0.00988* |
| ΔAST (IU/L) | 2.0 ± 5.9 | −2.2 ± 9.7 | 0.0324* |
| ΔALT (IU/L) | 3.4 ± 11 | −4.3 ± 13 | 0.0213* |
| ΔγGTP (IU/L) | 6.0 ± 15 | −5.2 ± 17 | 0.0116* |
| ΔeGFR (mL/min/1.73 m2) | −1.5 ± 7.1 | −3.5 ± 6.1 | 0.00585* |
| ΔACR (mg/gCr) | −0.07 ± 9.6 | −12.02 ± 8.4 | 0.0216* |
| ΔBNP (pg/mL) | 1.6 ± 7.8 | −3.2 ± 9.0 | 0.0421* |
| ΔhsCRP (mg/L) | 0.017 ± 0.16 | −0.013 ± 0.83 | 0.432 |
| ΔSBP (mmHg) | −1.7 ± 8.2 | −9.2 ± 12 | 0.0115* |
| ΔDBP (mmHg) | −2.90 ± 6.9 | −1.05 ± 10.5 | 0.409 |
Data are expressed as mean ± standard deviation. *P < 0.05. γGTP, gamma‐glutamyl transpeptidase; ACR, albumin‐to‐creatinine ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI body mass index; BNP, brain natriuretic peptide; BW, bodyweight; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; EMPA, empagliflozin; FBG, fasting blood glucose; HbA1c, glycated hemoglobin; HDL‐C, high‐density lipoprotein cholesterol; hsCRP, high‐sensitivity C‐reactive protein; LDL‐C, low‐density lipoprotein cholesterol; RLP‐C, remnant‐like particle cholesterol; SBP, systolic blood pressure; TG, triglyceride. (pvalues for intergroup comparison).